Study identifier:D8480C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I open-label study to assess the safety, tolerability and PK of ascending multiple oral doses of AZD2171 when co-administered with fixed multiple oral doses of ZD1839 (250mg or 500mg once daily) in patients with advanced cancer
advanced tumor
Phase 1
No
AZD2171, ZD1839
All
65
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer
Location
Location
Amsterdam, Netherlands
Location
Utrecht, Netherlands
Location
Nijmegen, Netherlands
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.